See more : Atlanta Limited (ATLANTA.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Pure Biologics Spólka Akcyjna (PUR.WA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pure Biologics Spólka Akcyjna, a leading company in the Biotechnology industry within the Healthcare sector.
- J Sainsbury plc (JSNSF) Income Statement Analysis – Financial Results
- Derwent London Plc (DWVYF) Income Statement Analysis – Financial Results
- American Finance Trust, Inc. (AFINO) Income Statement Analysis – Financial Results
- Porvair plc (PRV.L) Income Statement Analysis – Financial Results
- Thunderbird Resorts, Inc. (TBIRD.AS) Income Statement Analysis – Financial Results
Pure Biologics Spólka Akcyjna (PUR.WA)
About Pure Biologics Spólka Akcyjna
Pure Biologics Spólka Akcyjna, a biopharmaceutical company, engages in the research and development of biological drugs and non-systematic therapies in the field of immuno-oncology, autoimmunology, and rare diseases. It is involved in the production, purification, analysis, and characterization of antibodies and aptamers; and design, development, and validation of assays, as well as conducts research on technology platforms for selecting active molecules. The company offers PureApta, a modular platform for in vitro selection of modified aptamers for therapeutic and diagnostic use. It also engages in the development of non-systemic therapies for use in treating patients suffering from neurological autoimmune disorders, including neuromyelitis optica and myasthenia gravis. Pure Biologics Spólka Akcyjna was founded in 2010 and is headquartered in Wroclaw, Poland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 95.00K | 662.00K | 254.00K | 572.00K | 16.75M | 9.53M | 981.84K | 1.29M |
| Cost of Revenue | 2.67M | 6.07M | 4.28M | 273.00K | 3.96M | 2.84M | 103.55K | 179.61K |
| Gross Profit | -2.57M | -5.41M | -4.03M | 299.00K | 12.79M | 6.69M | 878.29K | 1.11M |
| Gross Profit Ratio | -2,709.47% | -816.77% | -1,585.43% | 52.27% | 76.37% | 70.19% | 89.45% | 86.06% |
| Research & Development | 0.00 | 23.79M | 20.58M | 18.39M | 14.93M | 4.61M | 3.06M | 0.00 |
| General & Administrative | 6.54M | 8.03M | 3.80M | 6.01M | 4.00M | 2.11M | 177.03K | 638.36K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.54M | 8.03M | 3.80M | 6.01M | 4.00M | 2.11M | 177.03K | 638.36K |
| Other Expenses | 22.61M | 11.25M | 2.66M | -12.55M | 13.16M | 5.21M | 1.09M | 890.39K |
| Operating Expenses | 29.14M | 19.28M | 6.46M | 11.86M | 17.16M | 7.32M | 1.26M | 1.53M |
| Cost & Expenses | 31.81M | 25.34M | 10.74M | 12.13M | 21.12M | 10.16M | 1.37M | 1.71M |
| Interest Income | 281.00K | 199.00K | 93.00K | 29.00K | 3.63K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 3.83M | 329.00K | 227.00K | 349.00K | 157.18K | 14.16K | 13.03K | 0.00 |
| Depreciation & Amortization | 5.78M | 2.50M | 2.92M | 3.11M | 2.25M | 210.68K | 104.33K | 48.71K |
| EBITDA | -26.08M | -22.78M | -7.53M | -8.30M | -1.64M | -464.51K | -247.58K | -384.21K |
| EBITDA Ratio | -27,449.47% | -3,324.47% | -2,968.11% | -1,450.52% | -21.84% | -4.87% | -25.22% | -29.81% |
| Operating Income | -31.72M | -24.63M | -10.48M | -11.56M | -4.37M | -631.02K | -386.25K | -419.45K |
| Operating Income Ratio | -33,387.37% | -3,720.39% | -4,126.77% | -2,020.28% | -26.07% | -6.62% | -39.34% | -32.54% |
| Total Other Income/Expenses | -3.98M | -974.00K | -1.28M | -202.00K | -325.00K | -58.33K | -26.48K | -13.47K |
| Income Before Tax | -35.69M | -25.60M | -11.77M | -11.76M | -4.55M | -689.34K | -412.72K | -432.93K |
| Income Before Tax Ratio | -37,572.63% | -3,867.52% | -4,631.89% | -2,055.24% | -27.15% | -7.23% | -42.04% | -33.59% |
| Income Tax Expense | 0.00 | 769.00K | 1.31M | 349.00K | 157.18K | -44.17K | -13.44K | -13.47K |
| Net Income | -35.69M | -26.37M | -13.07M | -12.11M | -4.70M | -689.34K | -412.72K | -432.93K |
| Net Income Ratio | -37,572.63% | -3,983.69% | -5,146.06% | -2,116.26% | -28.08% | -7.23% | -42.04% | -33.59% |
| EPS | -11.19 | -11.87 | -5.88 | -7.32 | -3.09 | -0.59 | -0.77 | -0.81 |
| EPS Diluted | -10.85 | -11.87 | -5.88 | -7.32 | -3.09 | -0.59 | -0.35 | -0.37 |
| Weighted Avg Shares Out | 3.19M | 2.22M | 2.22M | 1.65M | 1.52M | 1.17M | 536.31K | 536.31K |
| Weighted Avg Shares Out (Dil) | 3.29M | 2.22M | 2.22M | 1.65M | 1.52M | 1.17M | 1.17M | 1.17M |
Source: https://incomestatements.info
Category: Stock Reports